X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NVK002 (atropine) inhibits the muscarinic actions of acetylcholine, which is investigated for anti-allergy and dry eye syndrome and progressive myopia.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: NVK002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Details:
NVK002 (atropine) is an investigational, preservative-free, low-dose atropine eye drop, using Vyluma’s proprietary technology to address stability, tolerability, and safety and developed for the treatment of Pediatric Myopia.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: NVK002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nevakar
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
Details:
NVK002 (atropine) is a proprietary, investigational, low-dose, preservative-free atropine eye drop administered nightly as a potential treatment for the progression of myopia in children.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: NVK-002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Laboratoires Thea
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
NVK002 (atropine) is a proprietary, investigational, preservative-free eye drop administered nightly, which, if approved, would be the first-in-class pharmaceutical treatment for myopia progression in children.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: NVK002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nevakar
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
Details:
The agreement represents an expansion of the previously announced exclusive licensing agreement for the commercialization of NVK002 (having Atropine) in Europe and other select countries.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: NVK002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Laboratoires Thea
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 14, 2022
Details:
NVK002 (atropine) inhibits the muscarinic actions of acetylcholine, which is investigated for anti-allergy and dry eye syndrome and Myopia, Progressive.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: NVK002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2021
Details:
NVK002 (atropine) inhibits the muscarinic actions of acetylcholine, which is investigated for anti-allergy and dry eye syndrome and Myopia, Progressive.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: NVK002
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
